Klinikum der Stadt Ludwigshafen am Rhein gGmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is conducting studies aimed at improving outcomes for patients with heart failure. Trials also evaluate novel approaches for atrial fibrillation. Additional research focuses on recovery after myocardial infarction.
- Evaluation of new agents for post‑myocardial infarction cardiac remodeling
- Assessment of anticoagulant‑free strategies in atrial fibrillation
- Investigation of therapies to prevent heart‑failure hospitalization
- Safety profiling of emerging heart‑failure drugs
Klinikum der Stadt Ludwigshafen am Rhein gGmbH supports these cardiovascular investigations through its multidisciplinary cardiac unit.
Eye Diseases
Research at the site focuses on degenerative retinal conditions such as wet age‑related macular degeneration. Another key area is the progression of geographic atrophy. The team also studies macular edema secondary to retinal vein occlusion.
- Long‑acting intravitreal implants for neovascular AMD
- Gene‑editing therapies for geographic atrophy
- Comparative studies of anti‑VEGF dosing intervals
- Management of macular edema after retinal vein occlusion
The ophthalmology team collaborates with international partners to advance retinal therapeutics.
Hemic and Lymphatic Diseases
Clinical programs target blood‑cancer entities including acute myeloid leukemia. Studies also address diffuse large B‑cell lymphoma. Additional trials evaluate treatment strategies for multiple myeloma.
- Combination regimens for relapsed AML with IDH1 mutations
- Bispecific antibody therapy for refractory DLBCL
- Maintenance strategies after autologous stem‑cell transplant in multiple myeloma
- Novel agents for advanced Hodgkin lymphoma
The hematology department leverages its expertise in transplantation to support these studies.
Immune System Diseases
Studies address autoimmune disorders such as systemic lupus erythematosus. Research also investigates ANCA‑associated vasculitis. A further focus is on giant cell arteritis.
- Complement inhibition in active lupus nephritis
- Selective cytokine blockade in ANCA‑associated vasculitis
- Secukinumab for preventing relapse in giant cell arteritis
- Novel oral agents for systemic autoimmune disease
Klinikum’s rheumatology and nephrology units provide integrated care for trial participants.
Neoplasms
The site conducts oncology trials across solid tumors, including non‑small cell lung cancer. Investigations also target gastric adenocarcinoma. Another priority is therapy for melanoma.
- Immune‑checkpoint inhibitor combos in advanced NSCLC
- Targeted HER2 therapy for gastric cancer
- Adjuvant immunotherapy in resectable melanoma
- Biomarker‑driven trials in ovarian cancer maintenance
The oncology department works closely with university researchers to accelerate drug development.
Parasitic Diseases
Limited but focused research investigates treatments for scabies. Trials compare formulation strengths to determine optimal efficacy.
- Head‑to‑head comparison of permethrin 10 % versus 5 % cream
- Safety assessment of topical agents in diverse populations
- Evaluation of treatment adherence in community settings
Dermatology specialists ensure rigorous monitoring of trial outcomes.
Immune system processes
Investigations explore fundamental immune system processes underlying autoimmune diseases. The aim is to identify novel pathways for therapeutic intervention.
- Mechanistic studies of complement activation in renal disease
- Cell‑signaling analyses in vasculitis
- Biomarker discovery for treatment response in lupus
- Preclinical validation of immune‑modulating compounds
Cross‑disciplinary collaborations enhance the translational impact of these projects.
Miscellaneous / Unspecified
A subset of trials addresses conditions that do not fit into a single therapeutic category, focusing on safety and patient‑reported outcomes. These studies evaluate long‑term tolerability of emerging therapies across diverse populations.
- Long‑term safety extensions for gene‑therapy vectors
- Quality‑of‑life assessments in chronic disease cohorts
- Pharmacovigilance studies for new biologics
- Evaluation of diagnostic imaging biomarkers
The research infrastructure enables flexible study designs to meet emerging scientific needs.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 8 therapeutic areas and 15 of 120 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 118 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 21 by active trials.
- 1AstraZeneca AB4active
lock +20 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG7trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum der Stadt Ludwigshafen am Rhein gGmbH
lock Showing 1 of 59 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | Bayer AG | Phase III | Not Recruiting | Sep 2023 | May 2025 |
IMP list
lock Showing 1 of 120 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prednisone | 7 | Unknown | 2016-07-15 | 2025-02-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.